Please log in for more information
Catalent’s proprietary GPEx® technology generates high-performance, highly stable, production cell lines, allowing almost all complementary DNA (cDNA) types to be inserted into cells. To date, the technology has been proven in 16 commercially-approved products, and there are more than 160 ongoing clinical trials with therapeutic candidates developed using GPEx.
Leveraging next-generation technologies, GPEx Boost and GPEx Lightning, Catalent has enhanced the proven GPEx platform with a glutamine synthase knock-out CHO cell line and a novel gene insertion technology that can produce high titers and increase specific productivities of a protein of interest, as well as reducing drug substance development timelines.
Find out more...